Candela Stock Doubles In April As Aesthetic Lasers, Profits Attract Investors
This article was originally published in The Gray Sheet
Executive Summary
Continued strong demand for Candela's flagship aesthetic lasers, including the GentleLase for hair removal and ScleroPlus for vascular lesions, coupled with the release of strong third-quarter financial results ahead of some analysts' expectations, drove the firm's stock price in April. The issue gained 9-3/4 points to close at 18-3/4 for the month, an increase of 108.3%.
You may also be interested in...
Heartport Stock Up 97% In September On Acquisition Interest, New Products
Continued strong interest in minimally invasive surgery by cardiac surgeons, acquisition of competitors in the sector, a new CEO and several recent product introductions appeared to help stimulate a 97.3% gain in Heartport stock in September. The issue gained 2-1/4 points to close the month at 4-9/16.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”